Therapie der Endometriose

Ludwig Kiesel, L Kiesel, Karin Bertges, K Bertges, T R von Holst, T. Rabe, B Runnebaum, Th. von Holst
Archives of gynecology and obstetrics · 1989 · vol. 245(1-4) , pp. 937–940 · doi:10.1007/bf02417628 · PMID:2679444 · W2780816766
article OA: closed CC0 ⤵ 7 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06+body, 2026-06-07 ⓘ

Gestrinone and danazol both effectively treated endometriosis with similar pregnancy rates but different side effects, while buserelin induced implant reduction with estrogenic suppression side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This paper reports randomized trial evidence comparing hormonal therapies for endometriosis, including a study of 30 laparoscopically confirmed patients treated for 6 months with gestrinone versus danazol, and a multinational multicenter trial of 275 patients treated with the GnRH agonist buserelin intranasally. Across studies, treatment was effective in roughly 80–90% of cases, with similar pregnancy rates for gestrinone versus danazol, while buserelin induced disappearance or reduction of endometriotic implants in about 80%; the main side effects were attributed to estrogen suppression and differed between drug groups. A key limitation explicitly highlighted is the ongoing need to determine recurrence rates and long-term side effects, implying follow-up beyond the reported treatment periods is central. This paper is centrally about endometriosis — it compares gestrinone, danazol, and buserelin hormonal regimens and reports response and side-effect profiles.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Danazol Endometriosis Gestrinone Norpregnatrienes Pregnadienes Uterine Neoplasms Adult Danazol Endometriosis Female Gestrinone Humans Norpregnatrienes Pregnadienes Randomized Controlled Trials as Topic Uterine Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (11)

Cited by (7)

Source provenance

europepmc
last seen: 2026-06-22T06:15:23.361955+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:15.954262+00:00
License: CC0 · commercial use OK